ImmunoGen announces favorable STARLYTE Phase II Clinical Data with Sanofi’s SAR3419 in Diffuse Large B-Cell Lymphoma

02-06-2014 Business Wire HealthComments (0)


ImmunoGen (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentation of favorable clinical findings with SAR3419 (coltuximab ravtansine) from the STARLYTE Phase II trial in diffuse large B-cell lymphoma (DLBCL). SAR3419 is a CD19-targeting ADC developed by ImmunoGen and licensed to Sanofi as part of a broader collaboration between the companies. Th

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top